The Latest in Benign Prostatic Hyperplasia

Completed Studies

The Diagnostic Accuracy and Lower Cutoff Value of Three Methods for Quantifying Urethral Resistance in Men

Journal: Urologia Internationalis (September 24, 2010)

Authors: Zhao J, Zhao Z, Song J, et al

Purpose: The authors sought to determine “the diagnostic accuracy of Abrams-Griffiths number (AG), urethral resistance factor (URA) and detrusor-adjusted mean passive urethral resistance relation factor (DAMPF) for bladder outlet obstruction (BOO) in benign prostate hyperplasia (BPH) patients.”

Results: Of 172 cases, “154 were classified as obstructed and 18 as unobstructed.” The authors found that between the two groups, “there were statistically significant differences in AG, URA and DAMPF” while “the ROC curve demonstrated a similar diagnostic accuracy in the diagnosis of BOO for AG and URA values, and the least was seen for the DAMPF value.” Overall, researchers felt that “AG or URA appeared to be the best discriminating parameters of BOO in BPH patients. The DAMPF could be used to aid the BOO diagnosis. Lower cutoff values were suggested for these BOO parameters.”

Click here to access this third-party resource.

Clinical Characteristics of Bladder Urothelial Tumors in Male Patients - The Influences of Benign Prostatic Hyperplasia/Benign Prostatic Enlargement

Journal: Urologic Oncology: Seminars and Original Investigations (September 25, 2010)

Authors: Zhang N, Chen J, Ma L, Xu Z

Purpose: “To investigate the clinical characteristics of bladder urothelial tumors in male patients.”

Results: Researchers analyzed “the clinical characteristics of 356 patients with newly diagnosed bladder urothelial tumors from July 2005 to January 2010,” and found that “age is an unfavorable influence on the clinical characteristics of bladder urothelial tumors in men, and it was observed that the percentage of unfavorable tumors increased with age.” Furthermore, “there was a tendency for the men, who were diagnosed with benign prostatic hyperplasia/benign prostatic enlargement, to present with unfavorable carcinoma.”

Click here to access this third-party resource.

Currently Recruiting StudiesA Study in Men with Benign Prostatic Hyperplasia

Study Type: Interventional

Age/Gender Requirements: 45 years (male)

Sponsor: Eli Lilly and Company

Purpose: This phase II study will measure the “change from baseline to 24 week endpoint in International Prostate Symptom Score” total score; and Total Prostate Volume, Peak Urinary Flow Rate, Quality of Life Index, Prostate Specific Antigen, storage, voiding, and nocturia subscores; of subjects with lower urinary tract symptoms and prostatic enlargement secondary to BPH taking an experimental drug (LY500307). Patients will be randomly assigned to one of five study arms (1mg, 3mg, 10mg, 25mg, placebo).

Click here to access this third-party resource.

Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia

Study Type: Interventional

Age/Gender Requirements: 45 years (male)

Sponsor: Nymox Corporation

Purpose: This study will “evaluate the safety and efficacy of a 2.5 mg dose of NX-1207 for the treatment of BPH as compared to placebo.” Researchers will measure changes in the American Urological Association Symptom Index at 90, 180, 270, and 365 days, as well as the peak urine flow rate at 90, 180, and 365 days.

Click here to access this third-party resource.